Renaissance Technologies LLC cut its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 81.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,160 shares of the life sciences company’s stock after selling 235,340 shares during the quarter. Renaissance Technologies LLC owned about 0.06% of Integra Lifesciences worth $3,553,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Zeke Capital Advisors LLC acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth approximately $204,000. Eagle Boston Investment Management Inc. acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth approximately $223,000. World Asset Management Inc acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth approximately $261,000. Hsbc Holdings PLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $235,000. Finally, LS Investment Advisors LLC increased its holdings in shares of Integra Lifesciences by 99.3% during the 2nd quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock worth $275,000 after acquiring an additional 2,130 shares during the last quarter. 84.43% of the stock is currently owned by institutional investors and hedge funds.
IART has been the topic of a number of recent analyst reports. BidaskClub raised Integra Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Bank of America lowered Integra Lifesciences from a “neutral” rating to an “underperform” rating in a report on Tuesday, August 7th. They noted that the move was a valuation call. BTIG Research upgraded Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 price target for the company in a research note on Thursday, July 26th. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Finally, Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research note on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $62.15.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.60. The business had revenue of $366.20 million during the quarter, compared to the consensus estimate of $368.08 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The firm’s quarterly revenue was up 29.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.45 EPS. On average, research analysts expect that Integra Lifesciences Holdings Corp will post 2.4 EPS for the current fiscal year.
In other news, major shareholder Richard E. Caruso sold 46,676 shares of the company’s stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the sale, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Stuart Essig sold 69,871 shares of the company’s stock in a transaction on Tuesday, July 24th. The shares were sold at an average price of $63.54, for a total value of $4,439,603.34. Following the sale, the director now owns 1,438,367 shares of the company’s stock, valued at $91,393,839.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 126,463 shares of company stock valued at $8,013,188. Corporate insiders own 5.10% of the company’s stock.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: Short Selling
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.